Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylene Blue for Prevention of Postoperative Neurocognitive Disorders in Pancreatic Surgery
NCT04529265Completed
- Sponsor
- Fudan University
- Start
- May 2021
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of methylene blue in postoperative delirium (POD) and Post-operative cognitive dysfunction (POCD), sponsored by Fudan University. Primary endpoint: Incidence of Postoperative Delirium at 7 days. Started May 2021; status: completed.
02
Drugs
methylene blue
03
Conditions
postoperative delirium (POD)Post-operative cognitive dysfunction (POCD)
Beyond the preview
Go deeper on NCT04529265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04529265.